XASXIRX
Market cap4mUSD
Dec 27, Last price
0.03AUD
1D
0.00%
IPO
-90.45%
Name
Inhalerx Ltd
Chart & Performance
P/E
—
P/S
5.67
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
19.45%
Rev. gr., 5y
28.34%
Revenues
1m
+4,755.02%
Net income
-1m
L-23.90%
CFO
-2m
L+6.26%
Earnings
May 30, 2025
Profile
InhaleRx Limited engages in the developing and commercializing of medical drug delivery systems in Australia. It also develops inhaled drug formulations. Its solutions include Medihale inhaler, a sealed pod inhaler for use with inhaled formulations. The company was formerly known as Lifespot Health Ltd and changed its name to InhaleRx Limited in October 2021. InhaleRx Limited was incorporated in 2016 and is based in Sydney, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 1,204 4,755.02% | 25 -85.18% | 167 71.60% | |||||
Cost of revenue | 2,310 | 1,535 | 844 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (1,106) | (1,510) | (677) | |||||
NOPBT Margin | ||||||||
Operating Taxes | (1,204) | (16) | (334) | |||||
Tax Rate | ||||||||
NOPAT | 99 | (1,494) | (676) | |||||
Net income | (1,443) -23.90% | (1,897) 70.69% | (1,111) 9.87% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | (2) | 1,176 | 2,258 | |||||
BB yield | -11.33% | -14.97% | ||||||
| Debt | ||||||||
Debt current | 560 | (25) | ||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | (156) | (2,133) | (2,828) | |||||
| Cash flow | ||||||||
Cash from operating activities | (1,962) | (1,846) | (1,162) | |||||
CAPEX | (175) | (25) | ||||||
Cash from investing activities | (175) | (25) | ||||||
Cash from financing activities | 544 | 1,176 | 2,258 | |||||
FCF | (412) | (1,485) | (686) | |||||
| Balance | ||||||||
Cash | 716 | 2,133 | 2,803 | |||||
Long term investments | ||||||||
Excess cash | 656 | 2,132 | 2,795 | |||||
Stockholders' equity | 665 | 1,597 | 2,347 | |||||
Invested Capital | 570 | 306 | 306 | |||||
ROIC | 22.48% | |||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 189,356 | 173,051 | 167,571 | |||||
Price | 0.06 -33.33% | 0.09 16.88% | ||||||
Market cap | 10,383 -31.15% | 15,081 97.46% | ||||||
EV | 7,919 | 11,922 | ||||||
EBITDA | (1,106) | (1,501) | (675) | |||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||